Valeo Financial Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Valeo Financial Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$283K	Buy	+1,679	New	+$249K	0.01%	637
2020 Q3	–	Sell	-3	Closed	–	–	1949
2020 Q2	$0	Buy	+3	New	+$332	﹤0.01%	2113
2019 Q2	–	Sell	-10	Closed	-$1K	–	1625
2019 Q1	$1K	Hold	10	–	–	﹤0.01%	1467
2018 Q4	$1K	Hold	10	–	–	﹤0.01%	1394
2018 Q3	$1K	Buy	+10	New	+$1.14K	﹤0.01%	1648

Other funds holding NBIX

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

PBBUPS

PKO BP Bankowy Universal Pension Society Warsaw, Poland $350M AUM 272.18% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Ellsworth Advisors Hudson, Ohio $609M AUM 52.37% 1-Year Est. Return

PensionDanmark Copenhagen O, Denmark $12B AUM

YCM

Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return

COPPSERS

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

Valeo Financial Advisors's NBIX Position: Q2 2026 in Review

Valeo Financial Advisors opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 1,679 shares worth $283K. The stake represents 0.01% of the portfolio and ranks #637 among its holdings. This is a return to the name: Valeo Financial Advisors previously reported a position in NBIX as recently as Q2 2020.

Valeo Financial Advisors first reported a position in NBIX in Q3 2018 and has held it in 5 quarters since. 84 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Valeo Financial Advisors held 1,679 shares of Neurocrine Biosciences worth $283K as of Q2 2026.
Neurocrine Biosciences was a new Valeo Financial Advisors position in Q2 2026.
Neurocrine Biosciences made up 0.01% of Valeo Financial Advisors's portfolio in Q2 2026, its #637 holding.
Valeo Financial Advisors first reported a position in Neurocrine Biosciences in Q3 2018 and has held it in 5 quarters since.
84 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Valeo Financial Advisors's 13F filing for Q2 2026, filed 8 Jul 2026.